Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter